Tag: Leqembi

An estimated 7.2 million Americans age 65 and older are living with Alzheimer's in 2025 [1.7.2]. This staggering number fuels the urgent search for effective treatments, leading many to ask: What is the miracle drug for Alzheimer's?

Over 6 million Americans are affected by Alzheimer's disease, a leading cause of cognitive decline. Recent advances have led to FDA approval of new medications for cognitive decline, including Leqembi (lecanemab) and Kisunla (donanemab), marking a new era in treatment by targeting the underlying pathology.

According to clinical trial data, approximately 26% of patients treated with LEQEMBI experienced infusion-related reactions. As part of these reactions, it is documented that **LEQEMBI affects blood pressure**, causing temporary fluctuations that may include either an increase or decrease. Healthcare providers closely monitor patients for these changes during and after the intravenous infusion.

In clinical trials, Leqembi was shown to slow the rate of cognitive decline in early Alzheimer's disease by 27% over 18 months compared to a placebo, but some patients and caregivers still ask, "Can Leqembi make Alzheimer's worse?". The answer is complex, as it involves understanding the difference between the disease's natural progression and serious, drug-related adverse events.

In clinical trials for the Alzheimer's medication LEQEMBI (lecanemab), up to 12.6% of patients experienced brain swelling (ARIA-E) and 17.3% experienced brain bleeding (ARIA-H), which was higher than in the placebo group. While often asymptomatic, these side effects can, in rare cases, manifest with serious, stroke-like symptoms or lead to fatal brain hemorrhages, raising concerns about if **LEQEMBI can cause a stroke**. The U.S. Food and Drug Administration (FDA) has issued a black box warning to highlight this significant safety risk.

In the pivotal Clarity AD clinical trial, 12.6% of participants treated with Leqembi developed brain swelling (ARIA-E), a condition where confusion can be a key symptom [1.4.6]. The question of 'Can Leqembi cause confusion?' is directly linked to this and other potential side effects.

As of 2025, the U.S. Food and Drug Administration (FDA) has granted full approval to two amyloid antibodies for treating early-stage Alzheimer's disease: lecanemab (Leqembi) and donanemab (Kisunla) [1.2.1, 1.2.3, 1.2.4]. This article answers: **what amyloid antibodies are FDA approved** and details their use.

In clinical trials, common Leqembi side effects, such as infusion reactions and headaches, typically lasted for a few days to several weeks before resolving. However, the duration of side effects can vary significantly depending on the type and severity, with some serious adverse events like ARIA taking months to fully resolve.